SB 5526 is a comprehensive regulatory bill focused on tobacco products, alternative nicotine products, and vapor products in Washington. It expands and reorganizes state law to create a more detailed framework for licensing, age verification, product definitions, sales restrictions, manufacturer certification, product directory listing, inspections, recordkeeping, and enforcement. The bill also adds specific provisions addressing delivery sales, online sales, sales to minors, contraband products, and products containing nicotine analogues, while clarifying the roles of the Washington State Liquor and Cannabis Board and the Department of Revenue in administering and enforcing these rules.
A major feature of the bill is the creation of a manufacturer certification and directory system for vapor products containing nicotine. Manufacturers would have to certify compliance, disclose product information, and pay fees, and only certified products listed in the board’s directory could be sold in Washington after the phase-in period. The bill also establishes notice-and-cure procedures before removal from the directory, creates an enforcement account funded by fees and penalties, and authorizes seizure, forfeiture, destruction, civil penalties, license suspension or revocation, and injunctions for violations. It further imposes annual compliance checks, requires out-of-state manufacturers to appoint an in-state agent or post a bond, and authorizes rulemaking by the board.
The bill also updates tax and licensing provisions for tobacco products, including maintaining the existing excise tax structure and reinforcing that retailers and distributors must hold the proper licenses and obtain products only from licensed counterparties. It strengthens recordkeeping and inspection authority for distributors and retailers, and it treats certain violations as gross misdemeanors or class C felonies depending on the conduct. In addition, the bill preserves or clarifies exemptions and special treatment for tribal entities in certain provisions, and it includes confidentiality protections for some manufacturer-submitted information.
Because no committee transcripts or vote history were provided, there is no recorded public debate or roll-call sentiment to summarize from the available materials. Based on the bill text alone, the measure appears to be framed as a public health and enforcement bill, with an emphasis on youth access prevention, product oversight, and market accountability. The overall tone of the legislation is regulatory and enforcement-oriented rather than permissive.
The main points of contention likely center on the bill’s new compliance burdens for vapor-product manufacturers, distributors, and retailers, especially the directory requirement, certification fees, product removal procedures, and the possibility of seizure or license loss for noncompliance. Potential friction may also arise over the treatment of nicotine analogues, the scope of products covered, the role of the Liquor and Cannabis Board, and the impact on out-of-state or nonresident manufacturers. Retailers and industry stakeholders may view the bill as significantly expanding state control over vapor and nicotine markets, while public health advocates would likely support the tighter restrictions and enforcement tools.
SB 5526 would substantially amend Washington’s tobacco and vapor product statutes by adding new licensing, certification, directory, inspection, and penalty provisions, while also revising definitions and enforcement mechanisms across the chapter. It creates new obligations for manufacturers of nicotine-containing vapor products, requires product listing before sale, authorizes seizure and forfeiture of noncompliant products, establishes an enforcement account, and expands the Liquor and Cannabis Board’s authority to regulate, inspect, penalize, and remove products from the market. It also reinforces tax collection and licensing rules for tobacco products and adds a new prohibition on nicotine analogue products.
No committee testimony or vote record was provided, so there is no documented legislative sentiment to report from discussion or floor action. From the bill text, the measure is clearly intended as a public-health and enforcement bill, suggesting support from lawmakers concerned about youth access, product safety, and regulatory compliance. The overall framing is assertive and restrictive, indicating a strong regulatory posture toward tobacco and vapor markets.
The most likely areas of contention are the bill’s expanded regulatory burden on vapor-product businesses, especially the certification process, annual fees, directory listing requirements, compliance checks, and the risk of product seizure or license suspension for nonlisted products. Manufacturers may object to the confidentiality limits, in-state agent and bond requirements for nonresident firms, and the authority to remove products from the directory based on board determinations. Retailers and distributors may also contest the strict sourcing rules, inspection authority, and the new treatment of nicotine analogues, while public health supporters would likely favor these provisions as necessary to reduce youth access and improve oversight.